News from Omeros Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 11, 2016, 10:49 ET Omeros Announces Pricing of Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a...


Aug 10, 2016, 16:01 ET Omeros Announces Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald...


Jul 28, 2016, 09:27 ET Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency

Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection...


Nov 09, 2015, 16:10 ET Omeros Corporation Reports Third Quarter 2015 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and...


Nov 02, 2015, 07:00 ET Omeros Corporation to Announce Third Quarter 2015 Financial Results on November 9, 2015

 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule...


Oct 15, 2015, 07:00 ET Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®

 Omeros Corporation (NASDAQ: OMER) today announced that it has launched OMIDRIAssure™, a comprehensive reimbursement services program to...


Sep 03, 2015, 09:15 ET Omeros Files Infringement Suits Against Par

 Omeros Corporation (NASDAQ: OMER) today announced that it has filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its...


Mar 16, 2015, 16:05 ET Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results

 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and...


Feb 03, 2015, 17:01 ET Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants

Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on...


Jan 29, 2015, 08:32 ET Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a...


Jan 28, 2015, 16:01 ET Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

 Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common...


Nov 19, 2014, 07:00 ET OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients

 Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding...


Nov 10, 2014, 16:02 ET Omeros Corporation Reports Third Quarter 2014 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Nov 06, 2014, 07:00 ET Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke

Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721...


Nov 04, 2014, 07:00 ET Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Oct 30, 2014, 07:00 ET Omidria™ Granted Pass-Through Reimbursement Status from CMS

Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria™...


Oct 21, 2014, 07:00 ET Omeros Provides Update on PDE10 Inhibitor Program

 Omeros Corporation (NASDAQ: OMER) today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for...


Aug 11, 2014, 16:03 ET Omeros Corporation Reports Second Quarter 2014 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Aug 08, 2014, 07:00 ET Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on...


Jun 02, 2014, 07:00 ET Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and...


May 12, 2014, 16:05 ET Omeros Corporation Reports First Quarter 2014 Financial Results

Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing...


Apr 01, 2014, 07:00 ET Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference

 Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the...


Mar 19, 2014, 17:19 ET Omeros Closes $40.25 Million Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to...


Mar 13, 2014, 16:36 ET Omeros Announces Proposed Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock...


Mar 13, 2014, 16:16 ET Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results

Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing...